About
Treatment of Cognitive Disorders
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome. MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome. In 2017, six months after Alcobras clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.
Identity
| Name | Alcobra Pharmaceuticals |
|---|---|
| Slug | alcobra-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | alcobra-pharmaceuticals |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7fv_MIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Arcturus Therapeutics Inc. on Nov 2017 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Derech Menachem Begin 132, Tel Aviv-Yafo, Israel |
Web & social
| https://www.linkedin.com/company/5219796 | |
| Twitter / X | https://twitter.com/alcobrapharma |
Classifications
Funding
| Total raised | $25.0M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}